Gain Therapeutics Reports Promising GT-02287 Parkinson’s Data

Gain Therapeutics ( (GANX) ) has issued an announcement.

On March 18, 2026, Gain Therapeutics reported new clinical and biomarker results from its Phase 1b study of GT-02287 in Parkinson’s disease, presented in an oral session at the AD/PD 2026 conference in Copenhagen. Data from Part 1 and the ongoing nine‑month extension showed favorable safety, high patient retention and stable MDS‑UPDRS motor and daily living scores over 150 days of dosing.

Participants with elevated baseline cerebrospinal fluid glucosylsphingosine (GluSph) experienced substantial GluSph reductions after 90 days and a 6.7‑point advantage in combined MDS‑UPDRS Part II and III scores at Day 150 versus those with low baseline GluSph, while DOPA decarboxylase levels also fell in the high‑GluSph group, reinforcing the drug’s potential disease‑modifying effect. The company also unveiled preclinical data on a new, brain‑penetrant allosteric GCase modulator series led by GT‑04686, which has restored key biological functions in Parkinson’s models and is now positioned for IND‑enabling studies, underscoring Gain’s broader ambition to build a pipeline of GCase‑targeted therapies for Parkinson’s and other neurological disorders.

The most recent analyst rating on (GANX) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Gain Therapeutics stock, see the GANX Stock Forecast page.

Spark’s Take on GANX Stock

According to Spark, TipRanks’ AI Analyst, GANX is a Neutral.

The score is mainly held back by weak financial performance (minimal revenue, significant losses, and ongoing cash burn). Technicals also lean negative in the near term (below 20D/50D with subdued momentum). A positive offset is the encouraging Phase 1b update and stated runway through year-end 2026, but valuation is constrained by negative earnings and no indicated dividend.

To see Spark’s full report on GANX stock, click here.

More about Gain Therapeutics

Gain Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing next-generation allosteric small molecule therapies for neurodegenerative diseases, rare genetic disorders and oncology. Its lead candidate, GT-02287, targets glucocerebrosidase (GCase) to treat Parkinson’s disease with or without a GBA1 mutation and has potential in Gaucher’s disease, dementia with Lewy bodies and Alzheimer’s disease.

The company leverages its proprietary Magellan platform to identify novel allosteric modulators aimed at restoring or disrupting protein function. Gain also maintains multiple undisclosed preclinical programs in lysosomal storage disorders, metabolic diseases and solid tumors, expanding its footprint across high-need therapeutic areas.

Average Trading Volume: 1,093,703

Technical Sentiment Signal: Buy

Current Market Cap: $100.8M

Learn more about GANX stock on TipRanks’ Stock Analysis page.